London, Feb 17, 2026, 07:53 GMT — Premarket.
- GSK is set to kick off its fourth buyback tranche on Tuesday, aiming for as much as £0.45 billion.
- Shares finished Monday at 2,172 pence, a 0.3% uptick as they crept higher.
- Traders are eyeing two dates: Feb. 19, when the stock goes ex-dividend, and April 29, the scheduled release for first-quarter numbers.
GSK caught attention ahead of Tuesday’s London session, with the drugmaker announcing the launch of a fresh £450 million piece of its share buyback program.
This shift stands out with the stock hovering close to its recent peaks. Investors, looking for steady cash from big pharma, are holding on as they wait for updates on drug trials and any fresh deals from the new chief executive.
When a company buys back its own stock, it reduces the number of shares out there—typically a move that bumps up earnings per share. These buybacks can also help keep demand afloat during choppier trading sessions.
GSK shares closed Monday at 2,172 pence, a gain of 7 pence, the company’s share price screen showed.
GSK on Tuesday put out word that its fourth buyback tranche will total up to £0.45 billion, running from Feb. 17 through April 24. BNP Paribas has the mandate and will handle the buying under a non-discretionary deal. The company clarified that these shares are headed to treasury; no purchases planned for the U.S. or any ADRs.
The company said the buyback is part of a broader £2 billion initiative kicked off in February 2025, with plans to continue until the end of the second quarter of 2026.
GSK on Monday reported fresh share-based awards for several top executives, handing 3,020 notional shares apiece to Lynn Baxter, president for Europe, and Chief Patient Officer Mondher Mahjoubi. The awards come through a deferred investment plan, set to vest in 2029 and settle in cash.
Earlier this month, the company stuck to its 2026 guidance in its full-year report and kept the spotlight on getting new drugs through the pipeline. Management also highlighted continued payouts for investors, pointing to a planned fourth-quarter dividend for 2025.
GSK CEO Luke Miels is pushing for faster development and tougher calls on R&D, aiming to keep the company’s growth on track through the rest of the decade.
Investors face a real risk here: financial engineering has its limits. The share price remains highly sensitive to clinical trial results, regulatory calls, and missteps during product launches—particularly while the stock’s lingering near its highs.
Buyback flows are on traders’ radar ahead of the market open, as the Feb. 19 ex-dividend date draws closer. GSK’s next set of quarterly numbers lands April 29.
